Skip to main content

Advertisement

SpringerLink
Log in

Cytochrome P450 2C19 genetic polymorphisms in Ugandans

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L et al (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103–113

    Article  PubMed  CAS  Google Scholar 

  2. Sugimoto K, Uno T, Yamazaki H, Tateishi T (2008) Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol 65:437–439

    Article  PubMed  CAS  Google Scholar 

  3. Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E et al (2008) Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 65:767–774

    Article  PubMed  CAS  Google Scholar 

  4. Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J, Siuda A, Starzynska T, Drozdzik M (2006) Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 62:877–880

    Article  PubMed  CAS  Google Scholar 

  5. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E (2008) Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 83:322–327

    Article  PubMed  CAS  Google Scholar 

  6. Wang JH, Liu ZQ, Wang W, Chen XP, Shu Y, He N et al (2001) Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 70:42–47

    Article  PubMed  CAS  Google Scholar 

  7. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419–15422

    PubMed  Google Scholar 

  8. Herrlin K, Massele AY, Jande M, Alm C, Tybring G, Abdi YA et al (1998) Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther 64:391–401

    Article  PubMed  CAS  Google Scholar 

  9. Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M (2002) Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 12:375–383

    Article  PubMed  CAS  Google Scholar 

  10. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM et al (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187–5193

    Article  PubMed  CAS  Google Scholar 

  11. Bathum L, Skjelbo E, Mutabingwa TK, Madsen H, Horder M, Brosen K (1999) Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol 48:395–401

    Article  PubMed  CAS  Google Scholar 

  12. Dandara C, Masimirembwa CM, Magimba A, Sayi J, Kaaya S, Sommers DK et al (2001) Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol 57:11–17

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by “Fund for the Promotion of International Scientific Research.”

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan

    Jun Miura & Tomonori Tateishi

  2. Department of Pharmacology and Therapeutics, Faculty of Medicine, Makerere University, P.O. Box 7072, Kampala, Uganda

    Celestino Obua

  3. Department of Psychiatry, Faculty of Medicine, Makerere University, Kampala, Uganda

    Catherine Abbo

  4. Department of Neuropsychiatry, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan

    Sunao Kaneko

Authors
  1. Jun Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Celestino Obua
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Catherine Abbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sunao Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomonori Tateishi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Miura.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miura, J., Obua, C., Abbo, C. et al. Cytochrome P450 2C19 genetic polymorphisms in Ugandans. Eur J Clin Pharmacol 65, 319–320 (2009). https://doi.org/10.1007/s00228-008-0583-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-008-0583-6

Keywords

Search

Navigation